Drugs / SCD-044
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04684485 Comparator | Jul 2021 → Nov 2024 | atopic eczema | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04566666 Comparator | Mar 2021 → Nov 2024 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Announces Top-Line Results from the Phase 2 Clinical Trials Evaluating SCD-044 for Moderate to Severe Psoriasis and Atopic Dermatitis sunpharma.com ↗ |
| 2021-01-04 | Sun Pharmaceutical Industries, Inc. | Sun Pharma announces initiation of Phase 2 Clinical Trial of SCD-044 in Patients with Moderate to Severe Plaque Psoriasis sunpharma.com ↗ |
| 2020-05-28 | Sun Pharma Advanced Research Company Limited | SPARC and Sun Pharma enter into a worldwide license agreement for SCD-044, a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders sparc.life ↗ |
| 2019-12-19 | Sun Pharma Advanced Research Company Limited | SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044 SPARC acquires Bioprojet’s right s for SCD -044 sparc.life ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCD-044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04566666 ↗ |